Kornimate/medical-research-clean huggingface dataset:
chair rise and step ups on cardiopulmonary parameters among preserved ejection heart failure patients

Conditions: Heart Failure

Summary: to determine the effects of chair rise and step ups on cardiopulmonary parameters among preserved ejection heart failure patients


Eligibility criteria:
inclusion criteria: * diagnosed preserved ejection heart failure patients * both male and female * age \> 60 years * preserved ejection fraction ≥ 45 % * hf duration ≥4 years exclusion criteria: * end stage heart failure * acute coronary syndrome * functional status limited due to condition other than heart failure * inability to adhere to study protocols.
nutritional risk factors for hip fracture: a case control study

Conditions: Hip Fracture

Summary: low body mass index (bmi) is a risk factor for hip fracture, but it is unknown if it is the low bmi per se that increases risk of hip fracture or if specific micro-nutrients contribute. the investigators want to elucidate this aspect in a case control study studying micronutrients in serum and bone turnover markers of hip fracture patients compared with controls of the same age.


Eligibility criteria:
inclusion criteria: cases are admitted acutely for a femoral neck fracture, a trochanteric or a subtrochanteric femoral fracture. exclusion criteria: * hip fracture as part of multi-trauma or high energy trauma (defined as a fall from a higher level than 1 metre). one recent fracture in addition to the hip fracture (e.g. radius or shoulder) is acceptable. * regarded as moribund at admittance. * absence of a valid informed consent or assent.

Keywords: hip fracture risk factors vitamin k1 vitamin d bone turnover markers osteocalcin undercarboxylated osteocalcin bone specific alkaline phosphatase (balp) insulin like growth factor 1 (igf1) parathyroid hormone (pth)
heweizhixie capsuletherapy on patients with diarrhea

Conditions: Diarrhea

Summary: the objective of this study is to evaluate safety and efficacy of heweizhixie capsule in patients with diarrhea.

the objective of this study is to evaluate safety and efficacy of heweizhixie capsule in patients with diarrhea.this is a phase 4 open label trial, enroll 2400 patients with diarrhea primary outcome measure:percent of subjects with treatment success secondary outcome measures: number of unformed stools passed per 24 h period time (hours) from first intake to the last unformed stools change from baseline of leeds dyspepsia questionnaire score percent of subjects with ae.

Eligibility criteria:
inclusion criteria: 3 or more unformed stools in 24 hours male and female subjects between 18 and 80 years old signed informed consent exclusion criteria: subjects with serum alt more than 5uln or serum cr more than 442umol/l subjects are pregnant now, likely to become pregnant subjects, who in the opinion of the investigator, are not suitable candidates for enrollment.
biomarkers in patients with pancreatic cancer ("biopac")

Conditions: Pancreatic Cancer

Summary: no validated biomarkers to identify pc at an early stage and to predict treatment outcomes in the individual patient exist. the objective of the present study is to find diagnostic, prognostic and predictive biomarkers.

the overall survival of patients with pancreatic cancer (pc) is dismal and has only improved slightly during the last decades primarily due to combination chemotherapy. early detection of pc is difficult and less than 25% of all pc patients are operated. no validated biomarkers to identify pc at an early stage and to predict treatment outcomes in the individual patient exist. the objective of the present study is to find diagnostic, prognostic and predictive biomarkers, which can be used to 1) diagnose pc early in the disease course with high specificity and sensitivity, 2) improve prognostication, or 3) predict and monitor treatment effectiveness and tolerability for the individual patient. biopac is an observational and translational open cohort study with prospective collection of biological materials and clinical data in patients with pc treated in routine care and also patients who were suspicious for malignancy in the pancreas but then operated without evidence of malignancy. patients contribute with blood samples (i.e. serum, edta plasma and buffy coat, and blood in paxgenerna tubes) before operation or start of adjuvant or palliative chemotherapy and during treatment with blood sampling before 2. cycle of chemotherapy and longitudinally every time of ct scan until disease progression. this schedule is repeated if patients are treated with subsequent lines of chemotherapy. the patients are followed until death. demographics, disease characteristics, comorbidities and lifestyle factors are registered at inclusion; weight and performance status at each treatment cycle; routine blood tests (i.e. haematology, creatinine, liver enzymes, bilirubin, carbohydrate antigen 19-9, c-reactive protein); type of operation; types of chemotherapy and number of cycles given; date of disease recurrence in operated patients; date of disease progression for each line of chemotherapy; and date of death. biomarker analyses will include a range of molecules with different characteristics such as dna, single nucleotide polymorphism (snps), rna, microrna, proteins and metabolites. data will be analysed using appropriate methods and statistical analyses.

Eligibility criteria:
inclusion criteria: * age \> 18 years * histologically verified pc (ductal adenocarcinoma) or ampullary adenocarcinoma in a resected specimen; or histopathological confirmation of carcinoma in patients not undergoing surgery in the setting of clinical and radiological characteristics which, together with the pathology, are consistent with a diagnosis of pc independently of stage exclusion criteria: • none

Keywords: pancreatic cancer biomarkers biobank diagnostic biomarkers predictive biomarkers prognostic biomarkers
a clinical pharmacology study of saxagliptin in patients with type 2 diabetes mellitus

Conditions: Diabetes

Summary: the purpose of this study is to evaluate the pharmacokinetics and pharmacodynamics of saxagliptin administered before breakfast for 14 consecutive days in patients with type 2 diabetes mellitus.


Eligibility criteria:
inclusion criteria: * patients who meet all of the following criteria will be included: 1. hba1c level ≥7.0% and \< 9.0% 2. fasting glucose level ≥130mg/dl and \<210mg/dl 3. patients who are capable of giving informed consent 4. patients who are able to take contraceptive measures to avoid pregnancy of the patient or the patient's partner for the entire study period and for 4 weeks after completion of the study exclusion criteria: * patients with type 1 diabetes mellitus; patients with diabetes mellitus due to other specified drugs, mechanisms, or diseases; and patients with gestational diabetes mellitus * patients with a medical history of diabetic coma * patients with heart failure * patients with a complication of active chronic hepatitis or hepatic cirrhosis * patients undergoing treatment of glomerular diseases other than diabetic nephropathy * patients with a history or complication of malignant tumor

Keywords: diabetes, type 2
fmri-guided transcranial magnetic stimulation treatment for parkinson's disease

Conditions: Parkinson&#39;s Disease

Summary: the goal of this clinical trial is to compare the efficacy of targeting the newly discovered scan versus traditional effector-specific networks in m1 using multimodal imaging and rtms in patients with parkinson's disease. the main question it aims to answer is: is rtms targeting the scan more effective than rtms targeting effector networks?

parkinson's disease (pd) is a neurodegenerative disorder commonly affecting middle-aged and elderly individuals. besides conventional treatments such as medication (e.g., levodopa) and surgery (e.g., deep brain stimulation), non-invasive neuromodulation techniques, such as transcranial magnetic stimulation (tms), have been widely used as a safe and well-tolerated non-pharmacological adjunct therapy for pd patients. however, the limited efficacy of tms may be attributed to an incomplete understanding of pd-related cortical circuits and imprecise targeting. historically, the primary motor cortex (m1) has been selected as the repetitive tms (rtms) target for pd treatment. in 2022, gordon et al. discovered a new network within the m1 that differs from effector-specific networks responsible for executing movements of specific body parts, such as those for the foot, hand, and face. this newly identified network, named the somato-cognitive action network (scan), is located in inter-effector regions and is responsible for motor planning, control, and coordination. damage to this network correlates with key pd symptoms, making scan a promising new target for pd intervention. this study aims to compare the efficacy of targeting the newly discovered scan versus traditional effector-specific networks in m1 using multimodal imaging and intermittent theta burst stimulation (itbs), a rapid form of rtms. the objective is to provide new clinical evidence for non-invasive neuromodulation in parkinson's disease.

Eligibility criteria:
inclusion criteria: * diagnosis of primary pd per the mds clinical diagnostic criteria (2015) or the chinese parkinson's disease diagnostic criteria (2016). * age 18-75. * stable use of anti-pd medication for at least two months prior to enrollment. * normal cognitive function (mmse \> 24). * understanding of the study and signing of informed consent. exclusion criteria: * diagnosed with other neurological diseases, such as stroke, brain tumor, traumatic brain injury, motor neuron disease, alzheimer's disease, multiple sclerosis, etc. * implanted medical devices incompatible with mri, such as deep brain stimulators, pacemakers, cochlear implants, or vagus nerve stimulators. * conditions contraindicated for mri, such as claustrophobia, tattoos, or magnetic metal implants. * personal or family history of epilepsy. * prior neuromodulation treatments (e.g., tms, transcranial electrical stimulation, transcranial ultrasound stimulation) within the last three months. * other health abnormalities that the investigator deems unsuitable for study participation.

Keywords: tms parkinson&#39;s disease
mecillinam for treatment of genital chlamydia infection

Conditions: Chlamydia Trachomatis Infection; Chlamydial Urethritis

Summary: the mainstay of treating both symptomatic and asymptomatic genital chlamydia trachomatis infection has been macrolide antibiotics in the form of azithromycin, and alternatively tetracycline antibiotics in the form of doxycycline. studies from the late nineties found a single dose of 1 g azithromycin to be equally effective as a 7 day course of 200 mg doxycycline a day. however, recent studies have reported increasing treatment failure that may indicate that resistance to macrolide antibiotics among chlamydia trachomatis is evolving. research regarding other bacterial species indicates a high frequency of mutation based resistance in conjunction with azithromycin use, i.e. when treating mycoplasma genitalium infections. there has only been case reports of tetracycline resistance among human chlamydia isolates, but a recent study suggest that there might be decreasing effectiveness also for doxycycline. veterinaries has for several years observed increasing prevalence of tetracycline resistance among chlamydia suis. within the chlamydia population there is promiscuous horizontal gene transfer. if the current trend of declining cure rates continues, the investigators might face a situation where there are no documented and effective treatments for chlamydia trachomatis infections. this underline an urgent need to expand the number of documented treatment options and mecillinam seems to be one of the options that warrant further investigation. the objectives of this study is to prove the concept of treating genital chlamydia trachomatis with mecillinam (pivmecillinamhydrochlorid).


Eligibility criteria:
inclusion criteria: * proficient in oral and written norwegian * positive naat in first void urine for chlamydia trachomatis * negative naat in first void urine for mycoplasma genitalium * heterosexual male * asymptomatic exclusion criteria: * known allergies for mecillinam, penicillin or cephalosporines * metabolic anomalies of aciduric type * apparent underweight * use of mecillinam within the last two months * under treatment with valproat, other anti-infective drugs, immuno-modulating medication * in the opinion of investigator,obvious reasons why patient will fails to adhere to treatment and follow-up protocol

Keywords: chlamydia trachomatis urethritis genital diseases, male
milk free from a1-type β-casein on inflammation, gastrointestinal tolerance, and pregnancy outcomes

Conditions: Healthy Pregnant Women

Summary: the aim of the study is to compare the effects of conventional ultra high temperature (uht) milk containing both a1 and a2 type β-caseins (con) with a2 uht milk containing a2 type β-casein only (a1pf) on inflammation, tolerance, and gi symptoms in pregnant women as well as infants' birth outcomes from 12 weeks' gestation up to 40 days post-birth.


Eligibility criteria:
inclusion criteria: * 20-35 years of age * recruited at \<12 weeks of gestation * intention to deliver at study site hospital * singleton pregnancy * able and willing to consume milk during pregnancy * agree not to participate in another interventional clinical study during the present study exclusion criteria: * body mass index ≥ 35 at enrolment * cow's milk intolerance or allergy * significant systemic disorder (e.g., cardiac, respiratory, endocrinological, hemato-logic, or gi); pre-pregnancy diabetes, hypertension, or other medical conditions that preclude participation per the investigator's judgement * taking any prescribed chronic medications * participation in another clinical trial * investigator uncertainty about the willingness or ability of the participant to comply with the protocol requirements * taking probiotics at screening or two weeks before enrolment * receiving any vaccine at screening or two weeks before enrolment
optimisation of hydromorphone - naloxone ratio for the treatment of pain

Conditions: Constipation

Summary: the purpose of this study is to establish an optimal hydromorphone - naloxone ratio with an improved bowel function for constipated pain patients.

subjects suffering from cancer or non-cancer pain suffering from constipation cased or aggravated by opioids will be randomised to one of four ratios of hydromorphone pr plus naloxone pr or hydromorphone pr plus placebo to investigate whether a hydromorphone/naloxone combination will lead to comparable analgesia, with a decrease in constipation, and to investigate the optimal dose ratio of hydromorphone and naloxone.

Eligibility criteria:
inclusion criteria: 1. male or female subjects at least 18 years with a history of non-cancer or cancer pain that requires around-the-clock opioid therapy (8, 24 or 48 mg hydromorphone pr per day for the duration of the study). 2. subjects with constipation caused or aggravated by opioids 3. subjects must be willing to discontinue their current opioid analgesic routine, and . 4. current laxative regimen exclusion criteria: 1. chronic or intermittent pain that results from fibromyalgia or rheumatoid arthritis. 2. subjects presently taking, or who have taken, naloxone \<=30 days prior to the start of the screening period. 3. subjects suffering from diarrhoea. 4. abnormal liver or kidney function.

Keywords: confirmatory constipation pain hydromorphone naloxone
treatment of hyperlipidemia and sexual dysfunction

Conditions: Sexual Dysfunction; Hyperlipidemia

Summary: hyperlipidemias are frequently associated with and are considered an important cause of erectile dysfunction in men. this association has been attributed to the impairment of blood flow through endothelium-dependent relaxation in smooth muscle cells of corpus cavernosum. basic science and human research suggest that the vascular pathophysiology of male and female sexual dysfunction may be similar, as the first phase of the female sexual response is mediated by a combination of vasocongestive and neuro-muscular event which include increased clitoral length and diameter, as well as increased vaginal lubrication, wall engorgement and luminal diameter. the investigators have shown that women with hyperlipidemia had a higher prevalence of sexual dysfunction as compared with age-matched women without hyperlipidemia. the aim of this study was to asses the effect of anti-hyperlipidemic drugs (fenofibrate and rosuvastatin, single or in combination) on validated indices of sexual function in hyperlipidemic men and women with sexual dysfunction at baseline.


Eligibility criteria:
inclusion criteria: * low-density lipoprotein (ldl)-cholesterol levels \> 160 mg/dl, high-density lipoprotein (hdl)-cholesterol levels \ 150 mg/dl. * stable heterosexual partner relationship for the preceding 6 months. exclusion criteria: * pregnancy or less than 8 weeks postpartum. * diabetes mellitus (fasting glucose \> 126 mg/dl. * uremia. * multiple sclerosis. * chronic alcoholism (intake of ≥ 500g/wk). * cancer. * psychiatric problems. * symptomatic cardiovascular disease. * gynecological surgery. * pelvic trauma. * polycystic ovarian syndrome. * abnormal thyroid function.

Keywords: hyperlipidemia ldl-cholesterol hdl-cholesterol triglycerides iief fsfi male and female sexual dysfunctions
development and exploration of the effectiveness and feasbility of a digital intervention for type 2 diabetes mellitus

Conditions: Diabetes Mellitus, Type II

Summary: the study is conducted to assess potential effectiveness and feasibility of a comprehensive digital intervention for people with poorly-controlled type 2 diabetes mellitus (t2dm), to explore the intervention effects of a combined online and offline management for people with t2dm and ultimately to improve the accessibility of lifestyle intervention among participants with t2dm.

the study is a single-arm, non-randomized clinical trial conducted to assess potential effectiveness and feasibility of a comprehensive digital intervention for people with poorly-controlled t2dm, to explore the 16 weeks intervention effects of a combined online and offline management for people with t2dm and ultimately to improve the accessibility of lifestyle intervention among participants with t2dm. primary objective is to study the proportion of participants with decrease in hba1c by 0.6% by providing digital based lifestyle modifications. secondary objectives include to 1) estimate the change in hba1c, body mass index (bmi) and improvement in lipid profile components at week 16 compared with baseline readings; 2) to evaluate of the use of the ramadan risk score (idf-dar risk stratification scoring tool); 3) to evaluate the rate of fasting and diabetes complications (hyperglycaemia / hypoglycaemia) amongst muslims with t2dm during ramadan.

Eligibility criteria:
inclusion criteria: * participants diagnosed with t2dm; * hba1c 7% and above in the latest blood test valid up to 12months prior to recruitment; * age range between 20-70 years old; * bmi between 23-50kg/m2 exclusion criteria: * pregnant / breast feeding participants * participants on insulin therapy or non-insulin injectable medication * history of diabetes crisis (hyper or hypoglycaemia) in the past 6 months * blood pressure ≥ 160/100 mmhg * recurrent history of acute pancreatitis * decompensated liver cirrhosis * egfr \<60ml/min/1.73m2 * history of acute myocardial infarction/acute coronary syndrome(within the past 1 year), arrhythmias, heart failure (ny class ii -iv) * proliferative diabetic retinopathy-foot ulcer, gangrene * deep vein thrombosis of lower limbs(within the past 12 months) * intermittent claudication -history of cerebral haemorrhage or acute cerebral infarction (within the past 12 months) * history of active cancer * post-transplant/perioperative participants(defined as planned for operation for the next 6 months) * history of hypo or hyperthyroidism, including subclinical states * musculoskeletal injuries resulting in difficulty to perform physical activities * failure to provide consent * unable to perform activities of daily livings (adls) * unable to use whatsapp and youtube via mobile devices, e.g. phone or tablet.

Keywords: digital intervention
optic nerve sheath diameter in retrobulbar ultrasound as a surrogate measure for intracranial pressure before and after non-invasive strategies

Conditions: Intracranial Hypertension; Optic Nerve Sheath Diameter

Summary: measurement of the diameter of the sheath of the optic nerve in patients hospitalized in intensive care, with increased intracranial pressure (\> 20mmhg) as a substitute measure for diagnosis and follow-up before and after different non-invasive strategies. three groups were created in which, through strategies already proven and non-invasive (mannitol, hypertonic solution 7.5% nacl, reverse trendelenburg) to decrease the intracranial pressure, the optic nerve diameter measurement was performed and simultaneously the investigators monitored intracranial pressure through an intraventricular catheter continuously to determine if both correspond


Eligibility criteria:
inclusion criteria: * adult patients (≥ 18 years old) with traumatic or non-traumatic elevated icp (defined as greater than 20 mm hg for at least 10min) * hospitalized in icu * patients with icp continuous measurement through an intraventricular catheter * respiratory rate maintained at 10-18 breaths/min to maintain the end tidal carbon dioxide partial pressure between 35 and 40 mmhg * peak airway pressure \<35 cmh2o * positive end-expiratory pressure \<5 cmh2o exclusion criteria: * patients who had undergone cranial decompression surgery * patients with ocular pathology * patients who had previously undergone eye surgery
immunohistochemical (ihc) scoring for receptors expression in breast tissues

Conditions: Breast Cancer

Summary: the purpose of this study is the identification and classification of human tissues and cytology specimens and elements therein. computer aided technology to assist the pathologists to identify, quantify, characterize and report their findings with regards to one or more diagnoses they should perform. in particular and for example: the scoring of the number of elements and their protein (antibody) expression level within a paraffin embedded tissue section.


Eligibility criteria:
inclusion criteria: * well stained paraffin embedded tissue specimens exclusion criteria: * fade away slides

Keywords: receptors immunohistochemistry breast over expression of hormone receptors in carcinoma of the breast sues